Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis.

Yu-Qiong LinFeng YuHui-Jun ChenYuan-Rong DengJin LinYing XuXin ZhengJing-Wen ZhangJun-Feng Liu

Published in: Renal failure (2024)

The astragalus-RAAS blocker combination treatment is safe and improves outcomes; however, rigorous randomized, large-scale, multi-center, double-blind trials are needed to evaluate its efficacy and safety in stage III DN.

Keyphrases

double blind
angiotensin converting enzyme
diabetic nephropathy
placebo controlled
angiotensin ii
clinical trial
randomized controlled trial
metabolic syndrome
phase ii
insulin resistance